These abstracts from the American Society of Hematology’s 2018 annual meeting caught our attention for their potential impact on clinical practice and research in the field.
Oral Anticoagulants Show Benefit for Cancer Patients at High Risk of Venous Thromboembolism
Two new studies show that oral anticoagulants and prescreening for blood clots before starting cancer treatment may help prevent blood clots in high-risk cancer patients.
Molecular Data Helps Better Predict Survival for Patients with Myelodysplastic Syndrome
Newly developed tools should help physicians better predict how long MDS patients may live and who might benefit from hematopoietic stem cell transplant.
More Evidence that CAR T-Cell Therapy Works for Many Patients with Large B-Cell Lymphoma
Two new investigations show CAR T-cell therapy works for more than just model patients enrolled in clinical trials. Follow-up analysis and data show high-risk patients with comorbidities also responded to drug.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The Next Step in Immunotherapy for Myeloid Hematologic Malignancies
A multicenter team studied the safety of immunotherapy atezolizumab in patients with myelodysplastic syndrome who had either failed or never received conventional HMA therapy.
Good Response Rate for New Anemia Drug in Patients with Myelodysplastic Syndromes
An international team of researchers recently finished a phase 3 clinical trial to test the anemia drug luspatercept on patients with myelodysplastic syndromes.
Blinatumomab Trial: 66 Percent of Patients Achieve Remission from Acute Lymphoblastic Leukemia
Remission rates of elderly ALL patients on a novel, lower-toxicity immunotherapy regimen appear to at least equal those observed with conventional chemotherapy.
ASH 2018: Dec 1-4
Please join our staff as we participate or present in the following presentations at the 2018 ASH Annual Meeting.